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Abstract
Background: Congenital heart disease (CHD) is the most prevalent congenital malformation affecting 1 in 100
newborns. While advances in early diagnosis and postnatal management have increased survival in CHD children,
worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor
in the counseling of these pregnancies.
Methods: Eligible participants are women presenting at 20 to < 37 weeks of gestation carrying a fetus with CHD.
Maternal/neonatal recordings are performed at regular intervals, from the fetal period to 24 months of age, and
include: placental and fetal hemodynamics, fetal brain magnetic resonance imaging (MRI), functional echocardiography,
cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers. Neurodevelopmental
assessment is planned at 12months of age using the ages and stages questionnaire (ASQ) and at 24months of age with
the Bayley-III test. Target recruitment is at least 150 cases classified in three groups according to three main severe CHD
groups: transposition of great arteries (TGA), Tetralogy of Fallot (TOF) and Left Ventricular Outflow Tract Obstruction
(LVOTO).
Discussion: The results of NEURO-HEART study will provide the most comprehensive knowledge until date of children’s
neurologic prognosis in CHD and will have the potential for developing future clinical decisive tools and improving
preventive strategies in CHD.
Trial registration: NCT02996630, on 4th December 2016 (retrospectively registered).
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Background
Among congenital anomalies, congenital heart disease
(CHD) is the leading cause of childhood mortality and
morbidity, affecting up to 1% of all live births [1]. More
than 36,000 infants with CHD are born in Europe every
year and approximately 3000 more die in utero either
spontaneously through legal abortion or during neonatal
life [2]. Prognosis in these patients has significantly
improved in recent years, with survival up to 95%,
thanks to advances in diagnostic techniques and surgical
management [3, 4].
Up to 50% of children with CHD present deficits in at
least one area of neurodevelopment (learning ability, motor
skills, language, etc.) [5, 6]. These findings seem to be more
pronounced in CHD types associated with reduced oxygen-
ated blood brain delivery, such as transposition of great
arteries and left outflow tract obstruction; however, poor
neurodevelopment has also been reported in children with
heart defects with normal cerebral oxygen delivery [6].
Most studies evaluating neurological abnormalities in
children with CHD have focused on factors associated
with surgical repair [7], as abnormal neurodevelopment
was long believed to occur as a result of the procedures
associated with open surgery, mainly extra-corporeal
circulation. However, signs of brain injury on magnetic
resonance imaging and ultrasound have also been shown
in prenatal studies [8, 9]. Additional studies report that
CHD fetuses have smaller head biometries and signs of
brain sparing from the second trimester of pregnancy,
regardless of the type of CHD, supporting the recent
hypothesis of early onset appearance of noxa mecha-
nisms that could lead to a poorer neurodevelopment
later in life in these children [10, 11].
Moreover, pregnancies affected with a CHD fetus have
a higher rate of placental-related complications such as
preeclampsia and preterm birth [12], which increases the
chance of a poorer prognosis after birth and also after
surgery [13]. Some authors have described an existing
difference in plasma biomarkers in CHD, with higher
ratio of anti-angiogenic factors compared to pro-
angiogenesis factors and also increased blood levels of
brain and heart hypoxemic biomarkers [14], leading
to a possible related pathway between placental com-
plications and CHD, without being clearly defined.
Despite the importance and frequency of these compli-
cations, the prenatal and postnatal risk factors impacting
on neurodevelopment remain poorly understood. Stud-
ies from a clinical viewpoint have been based on small
series. Consequently, research into whether differences
exist in the spectrum of neurological damage according
to type of cardiac defect and what kind of neurodevelop-
mental deficits these children present is needed.
Our hypothesis is that the results of NEURO-HEART
study will provide the most comprehensive knowledge
until date of children’s neurologic prognosis in CHD
and will have the potential for developing future clinical
decisive tools and improving preventive strategies in
CHD to be used by cardiologists and obstetricians for
parental assessment.
Objectives
Aims
The NEURO-HEART study aims to: 1) Describe the
neuro-developmental outcome of patients with complex
CHD at 24months of age and identify a subgroup with
poorer outcome. 2) Evaluate the utility of fetal and postna-
tal (preoperative and postoperative) diagnostic techniques
for early recognition of patients at risk for suboptimal
neurologic outcome.
Methods
Participants/eligibility criteria
The participation of different referral centers will permit:
1. sufficient recruitment of fetuses to be distributed into
3 groups depending on their CHD and prospective fol-
low-up and integration of data from the prenatal period
to early childhood.
The study protocol was approved by each of the Ethic
Committee’s Centers, and written consent was obtained
from all women to participate in the study.
Settings/locations
 Hospital Universitari Vall d’Hebrón de Barcelona,
Spain
 Hospital Universitario La Paz de Madrid, Spain
 Hospital 12 de Octubre de Madrid, Spain
 Hospital Maternitat-Clínic de Barcelona, Spain
 Hospital Sant Joan de Déu de Barcelona, Spain
Recruitment and collection of data
Target recruitment is 150 cases classified in three groups
according to the specific type of CHD. After reviewing
existent literature and a variety of cohort classifications
[15–17] and being aware of the capacity of recruitment
due to our multicentric project, we decided to analyze
patients with very similar diagnosis as it appeared
inaccurate to create subgroups including different CHD
types and will also make future parental assessment
easier. Groups were made with our three most common
diagnosis: TGV, TOF and LVOTO. These groups are
known for having different patterns of blood supply to
the brain, being TGA and hypoplasic left heart
syndrome (HLHS) the ones with a higher oxygen impair-
ment [15], so we expect to obtain differences depending
on the CHD type. Cases are summarized in Table 1 in
Appendix.
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 Group 1: Transposition of great arteries.
 Group 2: Tetrallogy of Fallot.
 Group 3: Left outflow tract obstruction.
A control group of 50 low-risk pregnancies will also
be recruited. These patients will be followed up once a
month with fetal ultrasound at each visit; functional
echocardiography and MRI, performed at the same times
as in the case group.
See Table 1 in Appendix. Classification according to
CHD type.
Exclusion criteria
Pregnancies with gestational age < 20 weeks or > 38 weeks,
associated non-cardiac malformations, presence of
chromosomal abnormalities, associated arrhythmia and
maternal conditions that might affect fetal hemodynamics
such as diabetes, thyroid disease or preeclampsia, multiple
pregnancy and fetal anemia. Minimum age of inclusion
for the study will be 18 years old.
Database
The local research coordinator and/or the staff from
participating hospitals will identify eligible women and
after counseling and reading the information form, pa-
tients will be asked for written consent.
At study recruitment, demographic, obstetric and
medical history data will be recorded into a web-based
Case Report Form (CRF) that will be accessible through
a restricted website. Details on delivery, maternal and
neonatal assessments during pregnancy or post-partum
data will be recorded in the CRF. The collected data will
be coded and processed with adequate precaution to en-
sure patient confidentiality with the following measures:
Initials of participants as well as a local patient number
will be recorded in the electronic database. Linking
names with patients’ numbers will only be available in
the local clinics. Each participating clinic will receive a
login name and password to gain access to the web-se-
cured database. Database access will be restricted to cli-
nicians with electronic password. Full access to the
entire database will also be restricted to some members
of the research staff.
Procedures and interventions
Data collection
Patients will be followed up at the obstetrics and fetal
cardiology unit every 4 weeks with a multidisciplinary
approach. At inclusion, a blood sample from both par-
ents will be taken. During pregnancy, visits will be
scheduled every 4 weeks, including fetal biometries and
Doppler. At 28–32 weeks of pregnancy, a functional
echocardiography will be performed and finally, at 35–
37 weeks, a MRI for evaluating fetal brain will be done.
At delivery, a cord blood and a maternal blood sample
will be taken.
Mode of delivery, perinatal complications, biometric
data such birth weight and head circumference, need for
intubation or need for drugs after birth will also be re-
corded. A FCUS will be performed during the ICU stay.
Blood samples will be taken and continuous EEG for 2 h
will be performed before and after surgery. Brain oxim-
etry will be measured from 12 h before to 48 h after
surgery.
Children’s follow-up will take place at 12 and 24
months of corrected age. On both appointments, elec-
troencephalogram (EEG) and functional echocardiog-
raphy will be performed and a blood sample will be
obtained. At 2 years of age, a MRI will be performed.
Neurodevelopment follow-up will be performed at 12
months of age using the Ages & Stages Questionnaires
(ASQ) and at 24 months of age using Bayley-III Scale,
applied by a previously trained neuropsychologist. These
scores are widely used to determine the child’s perform-
ance compared with norms taken from typically devel-
oping children of the same age (in months).
Study procedures will be performed and organized as
shown in Fig. 1.
Ultrasound evaluation
Gestational age at scan will be calculated based on the
crown-rump length obtained at first trimester screening
[18]. A complete ultrasound examination will be per-
formed in each fetus using high quality ultrasound
systems.
Fetal biometric parameters assessed will include: bipar-
ietal diameter (BPD), head circumference (HC), abdom-
inal circumference (AC) and femoral length (FL).
Estimated fetal weight will be calculated according to
the method of Hadlock et al. [19]; both estimated fetal
weight and birth weight centile will be obtained using
local reference curves [20]. Doppler recordings will be
made in the absence of fetal movements with voluntarily
suspended maternal breathing. Measurements of pulsed
Doppler parameters will be taken automatically from
three or more consecutive waveforms, with an angle of
isonation as close to 0° as possible. Umbilical artery
(UA) will be evaluated in a free loop of the umbilical
cord; middle cerebral artery (MCA) will be measured in
a transverse view of the fetal skull at the level of its ori-
gin from the circle of Willis [21]. Cerebroplacental ratio
(CPR) will be calculated by dividing MCA by UA pulsa-
tility index (PI) [22]. Uterine artery (UtA) will be evalu-
ated with the probe placed on the lower quadrant of the
abdomen, angled medially, with identification by color
Doppler imaging of the apparent crossover with the ex-
ternal iliac artery. Mean uterine artery PI will be calcu-
lated as the average PI of right and left arteries [23].
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Fetal echocardiographic examination will be performed
according to the International Society of Ultrasound in
Obstetrics and Gynecology guideline [24]. Briefly, cardiac
axis and situs, pericardial effusions, ventricular morph-
ology, veno-atrial, atrioventricular and ventricule-arterial
connections, size and relationships of left and right
ventricular outflow tracts, ductal and aortic arches, atrial
and interventricular septum and flow through atrioven-
tricular and semilunar valves will be evaluated using two-di-
mensional, color and pulsed Doppler ultrasound. Prenatal
diagnosis of CHD will be confirmed using postnatal echo-
cardiography or autopsy in cases of neonatal death.
Functional echocardiographic scan will include several
measures [25]: from a transverse 4-chamber view in M-
mode: end-diastolic diameter (EDD), end-systolic diam-
eter (ESD), septum, myocardial wall thickness in systole
and diastole (calculation of shortening (SF) and ejection
fractions (EF)). From an apical/basal 4-chamber view in
2D: cardiothoracic ratio, atrial areas, AV valve diameters,
ventricular longitudinal and transverse diameters (calcu-
lation of sphericity indices). With an apical/basal 4-
chamber view, using pulsed Doppler, we will measure
early (E) and late (A) peaks of transvalvular filling veloci-
ties of left and right ventricles (E/A ratio calculation)
and the presence of mitral/tricuspid insufficiency and its
velocity. From an apical/basal 4-chamber view in M-
mode: mitral and tricuspid annular-plane systolic excur-
sion (MAPSE, TAPSE) will be measured. With an
apical/basal 5-chamber view in 2D, aortic valve diameter
in systole will be measured. Finally, with an apical/basal
5-chamber view adding pulsed Doppler, we will measure
aortic peak systolic velocity, measurement of the velocity
time integral (VTI), left fetal heart rate (calculation of
left cardiac output (CO)), left isovolumetric contraction
(ICT) and relaxation (IRT) times and ejection time (ET)
(calculation of myocardial performance index (MPI)).
Pulmonary valve diameter in systole, pulmonary artery
peak, systolic velocity, VTI and right fetal heart rate (cal-
culation of right CO, combined cardiac output (CCO)
and cardiac index (CI)) will also be measured. With a 3-
vessel and trachea view in 2D, the aortic isthmus and
ductus arteriosus diameters will be measured. In the
same plane with pulsed Doppler, aortic isthmus PI, sys-
tolic and diastolic VTI (calculation of isthmus flow index
(IFI)) and PI index will be recorded.
Myocardial peak systolic (S′) and diastolic (E’, A’)
velocities and myocardial performance index (MPI’) in
mitral, septal and tricuspid annuli will be also obtained
by tissue Doppler imaging with described previous
methodology [26].
MRI evaluation
Pregnant women will undergo fetal MRI on 1.5 Tesla
scanners at 35 to 37 weeks of gestational age following
the American College of Radiology guidelines for the use
of medical imaging during pregnancy and lactation [27].
T2-weighted images (HASTE) will be acquired in
sagittal, axial and coronal sections including all the brain
at 3.5 mm of thickness, as reported previously [28]. MR
spectroscopy (MRS) images will also be acquired in the
frontal lobe. Anatomical 2D images in sagittal, axial and
coronal sections will be acquired for volumetric recon-
struction. An anatomical control sequence (HASTE) will
be taken to verify the position of the fetal head has not
significantly changed, in which case the MRS images will
have to be repeated. Diffusion and MRS data will
additionally be acquired if possible. If the quality of the
images is suboptimal, sequences will be repeated.
Structural MRI images will be reviewed for the
presence of anatomic abnormalities by an experienced
neuroradiologist. Parameters evaluated will be: brain
calcifications if present, hypoxic or ischemic damage.
Brain biometric measurements will be performed using
the semiautomatic Analyze 9.0 software (Biomedical
Imaging Resource; Mayo Clinic, Kansas City, KS) by an
experienced examiner blinded to diagnosis. Cortical
fissure delineations in the fetal MRI will be performed
adapting previously described methodology to assess
Fig. 1 Study procedures flowchart
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cortical development in fetal ultrasound [29, 30] and will
include the following measures, performed as they have
previously been described for our group [31]: BPD,
fronto-occipital diameter (FOD), occipital fossa, cerebel-
lum diameter and lateral ventricular size, Sylvian fissure
depth, parieto-occipital suture depth and insula measure-
ments. In a middsagital plane, corpus callosum longitu-
dinal measurement and vermix diameter biometries will
be performed. Calcarine and Cingular fissures depth will
be measured in coronal plane. All biometric parameters
will be corrected by BPD and therefore expressed as ratios.
Cortical fissure depths will be measured bilaterally.
MRS data will be acquired from the semi oval centre,
with single voxel PRESS localization and will be proc-
essed in 2 ways using MATLAB R2010a (MathWorks
Inc., Natick, MA): method A, standard averaging of 128
transients (first free-induction-decay block discarded);
and method B, spectral sorting (discarding data with
gross artifacts and lipid contaminations) and alignment
(based on the residual water peak), before averaging.
Spectra will then be analyzed for quality assessment and
selection: both with jMRUI v4.0 (MRUI Consortium,
EU), spectral pattern well resolved for major peaks, such
as choline compounds, total creatine, and N-acetylaspar-
tate, and amplitude ratio of lipid (1.3–0.9 ppm) to cho-
line peak (3.21 ppm) < 10%; and with LCModel v6.3
(Stephen Provencher Inc., Oakville, Canada), peak full-
width at half-maximum < 0.1 ppm and signal-to-noise
ratio [32].
Postnatal MRI will be performed with a Siemens
Magnetom Trio 3.0 Tesla (Erlangen, Germany). T1
sequences will be taken for anatomical data. Qualita-
tive analysis on T2 and FLAIR frequencies will be
made with FSL software (functional magnetic reson-
ance imaging of the brain’s Software Library) [33].
MPRAGE imaging will be used for grey matter quan-
titative measurements and DTI images for white
matter measurements.
The presence of myelinisation in conventional sequences,
brain cortical development, ischemic or hemorrhagic
lesions and total grey /white matter volume will be
recorded. In addition, metabolic analysis will be made
and compared to data published in previous studies
[34]. All volumetric estimations will be obtained using
Cavalieri’s principle 27 by a multiplanar analysis con-
sidering a slice thickness of 3.5 mm with no gap
interval between them. For brain maturation evalu-
ation, specific MRI visual scores will be used [35].
Plasma biomarkers analysis
At the time of inclusion, a maternal venous blood sam-
ple will be drawn. Additionally, a second blood sample
will be taken from the mother at the time of delivery.
Blood samples from children with CHD will be drawn at
different time points: 1. after birth (cord blood) 2. during
the pre-surgery period and 3. immediately after surgery.
All blood samples will be processed within 1 h. Plasma
will be separated by centrifuge at 1400 g for 10 min and
stored at 4 °C.
Angiogenic Placental Growth Factor (PlGF) and
antiangiogenic soluble fms-like tyrosine kinase-1 and
soluble endothelin (sFlt1, sEng) factors will be mea-
sured in pregnant patients from both case and control
groups. In cord blood, the following biochemical
markers will be measured: a. markers of cardiac func-
tion and injury: Troponin I, N-Terminal pro-brain
natriuretic peptide (NT-proBNP), endothelin-1 and
heart fatty acid-binding protein (h-FABP); b. neuro-
logical damage markers S-100 proteins and neuron-
especific enolase (ENE) and c. angiogenic PlGF and
antiangiogenic sFlt1 factors.
All plasma biomarkers will be determined by ELISA
commercial kits following the manufacturer’s instruc-
tions. Angiogenic factors (PlGF, sFlt-1 and sEng) are
obtained from R&amp; D Systems (R&amp;D Systems
Europe Ltd., Abington, UK). Markers of cardiac func-
tion and injury are obtained from different manufac-
turers: Troponin I from AbFRONTIER (Young In
Frontier Co. Ltd. Seoul, Korea), NT-proBNP from BG
(BlueGene biotech CO. Ltd., Shanghai, China),
Endothelin-1 from R&amp;D Systems (R&amp;D Sys-
tems Europe Ltd, Abington, UK) and h-FABP from
Hycult Biotech (Hycult Biotech, Uden, The
Netherlands). Markers neurological damage (S100B
and NSE) are obtained from BG (BlueGene biotech
CO. Ltd., Shanghai, China).
Neonatal evaluation and neurodevelopment
During hospital stage, data on intensive care unit and
hospital length stay, need for mechanic ventilation,
need for vasoactive drugs and mortality will be
recorded.
Surgical duration, time on extracorporeal support,
cardiac ischemia time and the need and duration of cir-
culatory arrest will be also recorded. Need for renal
replacement therapies, extracorporeal life support and
cardiac arrest before or after surgery will be also
recorded.
Monitoring for oximetry and EEG will be recorded be-
fore and after surgery. Neurosonography will be used to
evaluate brain anatomy and findings such as: ventriculo-
megaly (VMG) and / or increased subarachnoid space;
signs of periventricular leukomalacia (PVL) signs of in-
traventricular hemorrhage (IVH); presence of calcifica-
tions and alterations in cortical development.
A baseline EEG of 12 channels will be performed
preoperatively and within the first 48 h postoperatively.
Ribera et al. BMC Pediatrics          (2019) 19:326 Page 5 of 10
Presence and number of power crisis and overall dur-
ation of delta waves will be recorded.
Following previous literature by Mebius et al. [36],
regional cerebral oximetry using technology Near-in-
frared Spectroscopy (NIRSS) will be recorded continu-
ously. NIRSS has been described as a useful predictor
for cardiac arrest in patients with complex CHD pre-
vious to surgery and a reliable way to measure brain
oxygen saturation. Bilateral forehead sensors will be
placed preoperatively (2 h prior to surgery) and will
be kept for at least 24 h post-operatively. Global per-
centage of time below a threshold of 45 and percent-
age of time below 20% of the baseline measurement
will be recorded.
Children will be followed up for 2 years. Cognitive
neurodevelopment will be assessed at 1 year of age
using the ASQ. This test is validated and extensively
used as a screening method for detecting impaired
neurodevelopment in high-risk children. Research
nurses will be notified when a patient will approach
the corrected age of 1 year by an email generated
from our database. After this alert, children’s parents
will be called to complete again the questionnaire. In
case the parents do not return the questionnaire, a
reminder will be sent. We will be using the validated
Spanish translation of the ASQ, covering the age-
range 4–60 months.
In the ASQ 3rd edition surveys, parents are asked to
answer “YES” (10 points), “SOMETIMES” (5 points) or
“NOT YET” (0 points) to a series of items of the follow-
ing categories of global neurodevelopment: communica-
tion, large movements, fine movements, problem solving
and socio-individual competence. A total score is ob-
tained from the sum of the items of each category. There
is a different baseline for every age and category under
which an alteration in this part of the neurodevelopment
is considered to exist. In our study, results were analyzed
as: a) impairment in each category; or b) impairment of
at least one category. Children scoring under 2 standard
deviations (SD) will be referred to diagnostic assessment.
At 2 years of age, Bayley-III Scale will be performed by
a previously trained neuropsychologist. This measure
consists on different developmental play tasks adminis-
tered between 45 to 60 min and derives in a develop-
mental quotient (DQ) rather than an intelligence
quotient. Raw scores of successfully completed items are
converted to scale scores and to composite scores. These
scores are used to determine the child’s performance
compared with norms taken from typically developing
children of their age (in months). The most recent
edition, the Bayley-III, has three main subtests: 1. the
Cognitive Scale, which includes items such as attention
to familiar and unfamiliar objects, looking for a fallen
object, and pretend play, 2. the Language Scale, which
taps understanding and expression of language and 3.
the Motor Scale, which assesses gross and fine motor
skills. The scaled score ranges from 1 to 19 points, with
a mean of 10 points in the validated population (USA),
and a SD of 3 points. Some studies question the capacity
of the Bayley Scale, especially the 3rd edition, for detect-
ing impaired neurodevelopment due to a tendency to
undervalue alterations [37]. For this reason, our study
defined impaired cognitive neurodevelopment as a score
of 8 or less on the scale (25th percentile, equivalent to
the mean minus 0.66 SD).
FCUS and MRI will also be performed at 2 years of
age.
At the same period of time, low-risk pregnant women
attending a routinely 20-weeks scan at Vall d’Hebron
Obstetrics Department would be asked for participation
as part of the control group of the study. In this group
of women, a blood sample at the time of the inclusion
and during delivery, as well as cord blood sample, will
be obtained. During pregnancy, visits will be scheduled
every 4 weeks and will include fetal biometries and
Doppler measurements. At 28–32 weeks of pregnancy, a
functional echocardiography will be performed and
finally, at 35–37 weeks, a fetal brain MRI will be done.
No further maternal or neonatal tests will be performed.
Outcome measures
Primary outcome mesures
A. Neurodevelopmental outcome according to CHD
types.
1. Abnormal ASQ: ASQ score results will be
compared to the normal Bell curve results for the
same age. Those close to the cut-off of 2 SD will be
considered at risk for neurodevelopment
impairment.
2. Bayley-III test will be considered at risk for
neurodevelopment delay when scored 8 or less on
the scale (25th percentile, equivalent to the mean
minus 0.66 SD)
Secondary outcome mesures
1. Hemodynamic changes and Doppler fetal cardiac
function in fetuses with CHD by type.
2. Cortical brain development assesed by MRI such as
changes in fissure depths, head biometries or brain
metabolism spectroscopic parameters.
3. Fetal head biometries and perfusional parameters.
4. Biochemical markers in cord blood associated with
neurological damage in children with CHD.
Ribera et al. BMC Pediatrics          (2019) 19:326 Page 6 of 10
5. Parameters of perioperative brain.
6. Severe neonatal or child morbidity will be taken
into consideration as primary outcome in our
trial. The presence of one or several of the
following complications will define severe
morbidity: severe respiratory distress,
intraventricular hemorrhage grades III-IV, treated
ductus arteriosus persistence, renal dysfunction,
necrotizing enterocolitis, intestinal perforation,
early and late sepsis, retinopathy of prematurity
treated with laser, bronchopulmonary dysplasia,
periventricular leucomalacia, postnatal
administration of corticosteroids or inotropic
drugs and/or death.
7. Statistical association of all the parameters
described in 1–5 with neurological development.
8. Regression statistical measures to select the most
valuable variables related to neurological
impairment in order to identify risk factors for
brain damage in a preoperative stage.
All these measures will be analyzed in an exploratory
manner. Analysis will be performed to investigate the
utility of pre- and post-natal markers in the short-term
prediction of adverse neurological outcomes in order to
create prognostic tools for early detection of patients at
risk.
Statistical analysis
Sample size
All participating centers together have over 25,000 deliv-
eries / year and more than 150 births of congenital heart
defects babies We have planned a 3 year-period recruit-
ment that, considering our previous birth statistics, cases
of interruption of pregnancy and an estimated 10% loss
of follow up, will allow us to recruit 60 patients diag-
nosed with TGA, 30 patients with TOF and 30 patients
for the LVOTO group, the largest series published so
far.
Data analysis
Storage of variables will be done in a database spe-
cially designed for our study by the Department of
Bioinfomatics and Clinical Pharmacology (HUVH).
Once the sample collection and conducting of labora-
tory determinations will be finished, we will proceed
to the evaluation and analysis of the results obtained
with help and advice by Bioinformatics Research In-
stitute Unit and the Support for Investigation Unit
(USMI) from Vall d’Hebron Hospital.
Statistical analysis
Data will be collected, digitalized and stored in a
data base designed for the study. The statistical
analysis will be based on single variable descriptive
models. In case of finding associations with
confusion factors, multivariable models will be
considered.
All statistical comparative analysis will be done using
SPSS 2.13 (SPSS for Windows, SPSS Inc., Chicago, Ill.,
USA) and MatLab statistical programs (2007b, The
MathWorks Inc., Natick, USA). In hypothesis testing for
population inference, statistical significance of 0.05 will
be postulated.
For the analysis of blood sample biomarkers all param-
eters will be transformed to MoMs as well as ultrasound
biometric and Doppler parameters will be converted to
z-scores using previously published data [38–40] in
order to compare data obtained in different gestational
age. MRI measurements will be corrected by BPD and
birth weight centile.
For multiple comparsions between groups one-
way ANOVA tests will be performed. In case of
non-parametric data, Mann-Whitney tests will be
used.
Also multivariate analysis using logistic regression
will be made with the support of the Unidad de
Soporte en Metodología para la Investigación Biomé-
dica (USMIB) using the application STATA v.11.Dif-
ferent analyses will be carried out in order to
establish the association and prediction power of the
characteristics analyzed in all tests independently and
also combined by implementing classical statistic
methods (linear and logistic regression) and inference
methods with and without a priori assumptions
(Bayesian networks, decision trees, principal compo-
nent analysis among others). After that, the results
will be implemented in a learning machine for
algorithms in MATLAB (2007b, The MathWorks Inc.,
Natick, USA). The type of analysis will depend on
each specific objective.
Limitations of the study
Establishing specific associations to a single CHD type
may require a larger sample size than we will be able
to recruit, especially in the Fallot and LVOTO
groups. Although our time to include patients may
not be enough to obtain the necessary number of
cases, we believe they will still be remarkable series
and a unique opportunity to create a CHD population
cohort.
We are aware that the LVOTO group is intrinsically
heterogenical with different prognosis and probably also
different brain development impairment between a coar-
tation of aorta and a hypoplasic heart syndrome case,
but this pathophysiological classification allows a reason-
able approach.
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Inclusion of healthy controls with the same follow up
has its logical limitations, and due to ethical considerations,
no control children would be used for biochemical
markers.
Discussion
Congenital heart disease is one of the leading causes of
congenital malformation. While advances in early diag-
nosis and postnatal management have increased survival
in CHD children [3], worrying long-term outcomes, par-
ticularly neurodevelopmental disability, have emerged as
a key prognostic factor in the counseling of these preg-
nancies [41, 42].
A recent study showed that a high proportion of
fetuses with CHD already have a smaller head and
increased brain perfusion in the second trimester of
pregnancy [15]. Additionally, a substantial percentage
of newborns with CHD have signs of brain injury on
magnetic resonance imaging and reduced cranial size
[43], suggesting an early onset of the mechanisms
leading to poorer neurodevelopment later in life
[44]. It has been hypothesized that altered cerebral
perfusion is one of the main contributors to abnor-
mal neurodevelopment in fetuses with CHD. Al-
though abnormal head size was more pronounced in
fetuses with compromised blood delivery to the
brain, it was also present in milder forms of CHD,
suggesting that there could be additional mecha-
nisms that contribute to abnormal neurodevelopment
in CHD cases [12, 45–47].
No prospective studies have been performed to allow
clinicians to do a good assessment on neurological prog-
nosis with compelling evidence until now. Differences in
brain development markers have not been reported in
previous series, but we believe those results might be re-
lated to sample size [48].
The Neuro-Heart trial aims to compare and de-
scribe preoperative markers on CHD affected fetuses
both prenatal as well as postnatal brain functional
monitoring during the perioperative period and
through cardiac surgery. At the same time, this multi-
centric trial will allow CHD patients included to be
classified into specific CHD groups in the largest
series published so far.
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Appendix
Table 1 Classification according to CHD type
Group 1: Transposition of great arteries
• With or without VSD.
Group 2: Tetralogy of Fallot
Group 3: LVOTO
• Coartation of aorta
• Aortic arch hypoplasia
• Double-inlet left ventricle with coartation/aortic arch hypoplasia
• Double outlet right ventricle with coartation/aortic arch hypoplasia
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